A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma
Inclusion Criteria:
- Pathologically confirmed NK/T-cell lymphoma
- Localized (Ann Arbor stage I/II) disease
- At least one measurable lesion
- Age > 18
- ECOG performance status 0 - 2
- Expected life span of at least 12 weeks
- Normal marrow function (hemoglobin ≥ 9.0 g/dL; absolute neutrophil count ≥ 1,500/mm3;
platelet count ≥ 100,000/mm3)
- Normal liver function (total bilirubin < 2x upper limit of normal [ULN], transaminase
< 3x ULN)
- Normal renal function (serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 50
mL/min)
- Written informed consent
Exclusion Criteria:
- Other malignancies except for treated non-melanoma skin cancers and cervical cancer
in situ
- Serious medical illnesses (congestive heart failure, angina, respiratory failure, and
renal failure)
- Acute or active infection requiring intravenous (IV) antibiotics
- Pregnant, lactating women
- Previous history of chemotherapy or radiotherapy
- Concomitant medication that may influence the study drugs
- Allergic reaction to study drugs
- Grade 2 or greater peripheral neuropathy